An open-label, randomized, single dose, two period, crossover study to determine the relative bioavailability of valsartan 160 mg Japanese formulation and valsartan 160 mg global formulation in healthy adult volunteers

Trial Profile

An open-label, randomized, single dose, two period, crossover study to determine the relative bioavailability of valsartan 160 mg Japanese formulation and valsartan 160 mg global formulation in healthy adult volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2007

At a glance

  • Drugs Valsartan (Primary)
  • Indications Essential hypertension; Heart failure; Hypertension; Postmyocardial infarction
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 29 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top